Psychosis Clinical Trials

A listing of Psychosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
TMCU for Young Adults With First Episode Psychosis

We propose to pilot test an adapted version of the Teen Marijuana Check Up (TMCU) for persistent cannabis users with first episode psychosis (FEP) in Coordinated Specialty Care (CSC). The

  • 0 views
  • 04 Oct, 2022
  • 1 location
Improving Family Engagement in Coordinated Specialty Care for First Episode Psychosis

episode psychosis. First, 5 family member participants will be recruited into a three-month trial of FAMES and implementation toolkit. The investigators will then conduct a 16-month non-randomized

  • 0 views
  • 04 Oct, 2022
  • 1 location
Acceptance and Commitment Therapy-based Lifestyle Counselling Programme for Early Psychosis on Physical Activity

-LCP) on the physical and psychosocial health outcomes of patients with early psychosis over a 12-week follow-up.

  • 21 views
  • 07 Oct, 2022
  • 1 location
Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia (OXYGEN)

Recent studies indicated positive effects of mindfulness-based interventions (MBI) for schizophrenia (SCZ), but also on oxytocin (OXT) levels in healthy persons. It was also shown that response to MBI could be shaped by genetic factors. However, the interplay between mindfulness and empathy and genetic factors with the oxytocinergic system has …

  • 0 views
  • 04 Oct, 2022
  • 1 location
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

disorder may be effective at reducing psychosis or altering the course of the disease, there are currently no biomarkers capable of identifying subjects in early stages of SZ who are likely to respond to

Accepts healthy volunteers
  • 7 views
  • 04 Oct, 2022
  • 1 location
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease Dementia (ADEPT-1)

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease dementia. The

  • 0 views
  • 27 Oct, 2022
  • 1 location
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs

Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC

Accepts healthy volunteers
  • 9 views
  • 15 Oct, 2022
  • 3 locations
Self-management of Stress and Sleep Disturbances With Virtual Reality Relaxation (Relax XL)

Stress is a well-established factor in the onset and continuation of burn-out anxiety, mood and psychotic disorders. Furthermore, sleep disturbances predispose and exacerbate mental health

  • 0 views
  • 04 Oct, 2022
  • 2 locations
An Open-label Extension Trial of Individualized Repetitive Transcranial Magnetic Stimulation in Patients With Auditory Verbal Hallucinations Who Completed Protocol #8116

schizoaffective disorder who previously completed the treatment study of the protocol #8116 (NCT05319080). Protocol #8116 investigates the clinical efficacy of open-label individualized MRI-guided TMS applied to

  • 0 views
  • 12 Oct, 2022
  • 1 location
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia. The overall aim is to establish neuroimaging biomarkers of the Dopamine Receptor 1/Dopamine Receptor 5 Family (D1R/D5R) target engagement to accelerate development of D1R/D5R agonists …

  • 24 views
  • 04 Oct, 2022
  • 4 locations